Turnarounds are rarely binary.

Management may improve the company and still not improve it fast enough.

That was the communication challenge around Sanofi’s February 2026 decision not to renew CEO Paul Hudson’s mandate and to appoint Belén Garijo.

Hudson had delivered progress in some areas.

Shareholder returns were positive.

The company still faced questions around pipeline renewal, vaccines and the pace at which the business was becoming less dependent on major products.

This is harder to communicate than simple failure.

Executive Authority Answer

When a board replaces a CEO after a partial but insufficient turnaround, it should acknowledge progress honestly, explain what the next phase now requires, distinguish pace from total failure, and show why the successor’s capabilities fit the unresolved problem. The communication should not rewrite the outgoing CEO’s entire tenure merely to justify change.

Boards damage credibility when they rewrite history

The outgoing CEO cannot be excellent on Monday and a failure on Thursday simply because the board changed leadership.

Stakeholders remember prior praise.

The stronger message is nuanced.

Progress occurred.

The remaining challenge changed or proved harder.

The board now wants different leadership for the next phase.

“Not fast enough” is a legitimate board judgement

Execution speed matters.

In pharmaceuticals, patents expire.

Pipelines age.

Competitors launch.

Clinical failures compound.

The board can reasonably conclude that a strategy needs faster results.

That does not mean every prior decision was wrong.

The successor should be connected to the unresolved problem

Why this person?

Scientific pipeline?

Commercial execution?

Portfolio management?

Operational discipline?

International experience?

The appointment becomes more credible when capabilities map to the problem.

The board should state what remains strategically intact

Is the scientific direction changing?

The portfolio?

Vaccines?

Capital allocation?

If strategy continues, say so.

If strategy changes, say that instead.

Avoid making stakeholders infer from the leadership change.

A CEO transition after slow progress creates internal ambiguity

Employees may ask:

Was the strategy wrong?

Were targets missed?

Will projects stop?

Will the new CEO reorganise everything?

Internal communication should reduce that uncertainty.

The outgoing CEO’s dignity matters

A board can be decisive without humiliating the departing leader.

This protects culture.

Senior executives watch how the institution treats leaders when they leave.

Pipeline businesses make turnaround communication especially difficult

Results are delayed.

Clinical development takes years.

Current management may inherit old bets and leave before new bets mature.

Boards need to distinguish lag from leadership failure.

That requires sophisticated judgement.

The board should explain its time horizon

How long was management given?

Which milestones mattered?

What progress was insufficient?

Not every detail needs publication.

The governance logic should exist.

A sudden change can look panicked

If the board has been praising the strategy, an abrupt CEO change may surprise the market.

The announcement should explain why now.

Contract renewal.

Milestone.

Strategic phase.

Board review.

Timing should have a logic.

The appointment should not imply a miracle

The successor inherits the same industry constraints.

Clinical uncertainty.

Regulation.

Competition.

Patent cycles.

The board should avoid language suggesting one person solves everything.

“New growth phase” needs definition

What makes the next phase different?

More launches?

Different R&D productivity?

M&A?

Commercial acceleration?

Margin?

A phrase is useful only when stakeholders can eventually see it.

The board should preserve accountability for its own oversight

If progress was too slow, the board was overseeing that progress.

Directors should not communicate as though the CEO operated alone.

Leadership change is also a governance decision.

The transition should have a clear interim structure

Who runs the company before the new CEO arrives?

What decisions can the interim leader make?

What waits?

This matters in a sector where decisions can have large long-term value.

Investors will compare successor and predecessor immediately

That comparison can become simplistic.

The company should define the successor’s mandate, not merely their biography.

What is the work?

What should be different?

What is the first evidence?

A turnaround should have predetermined milestones

Boards can reduce hindsight bias by defining milestones before evaluating the CEO.

Pipeline events.

Launches.

Margins.

Portfolio decisions.

Growth.

Then leadership assessment becomes less subjective.

The outgoing CEO’s own acknowledgement can matter

Hudson had acknowledged that progress was slower than desired.

That makes the board decision easier to contextualise.

The company should not exploit the quote unfairly.

It can show that pace was a recognised issue.

The board should distinguish patience from tolerance

Turnarounds require time.

That does not mean unlimited time.

The board’s role is to decide whether further patience is justified by evidence.

Culture hears leadership replacement as a signal

Which behaviours are being rewarded?

Speed?

Innovation?

Commercial performance?

Accountability?

The appointment communicates priorities whether the board intends it or not.

The successor should not launch immediate blame

A new CEO inherits a team.

Opening with criticism of the past can destabilise execution.

Review first.

Then decide.

A useful board announcement structure

Recognition.

What did the outgoing CEO accomplish?

Unresolved issue.

What still needs to improve?

Next-phase requirement.

What capability matters now?

Successor fit.

Why this person?

Transition.

Who is accountable when?

This creates a humane and strategic announcement.

The board should avoid “fresh start” clichés

A company does not become new because the CEO changes.

The successor inherits assets, obligations and constraints.

Specificity is stronger than symbolic reset language.

What another board should borrow

Borrow the distinction between progress and sufficient progress.

Borrow the mapping between successor capability and unresolved problem.

Borrow respectful treatment of the outgoing leader.

Borrow a clear next-phase mandate.

What another board should avoid

Do not rewrite the outgoing CEO’s record.

Do not imply one person caused every weakness.

Do not promise instant recovery.

Do not leave strategy continuity ambiguous.

Business outcome is separate

Garijo’s future success will determine whether the appointment proves wise.

The communication lesson concerns how the board explains the decision at the moment it is made.

Partial progress can still be insufficient.

The board’s job is to make that judgement legible.

Executive Summary

Sanofi’s February 2026 CEO change is a useful case because the outgoing leader had not simply failed. The company had made progress, but the pace and pipeline challenge remained unsatisfactory. The transferable lesson for boards is to resist rewriting history. A credible transition acknowledges what improved, states what remains unresolved, explains why the next phase requires different leadership and connects the successor’s capabilities directly to that mandate.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Final executive decision test

Before this communication is approved, leadership should identify the hardest reasonable objection, answer it with evidence rather than reassurance, state what remains uncertain, and define what future fact would force a change in judgement. Different audiences may require different detail, but they must not receive different realities. The next update should be planned now so the organisation returns with evidence rather than another slogan.

The board should explain whether the mandate changed

Sometimes the CEO is replaced because performance failed against the original mandate.

Sometimes the environment changes and the board wants different skills.

Those are different stories.

The company should know which one applies.

Pharmaceutical leadership requires patience and urgency at once

Drug development is slow.

Patent cliffs are not.

This is why boards must distinguish scientific patience from organisational delay.

The communication should reflect both.

The next CEO should receive a clean mandate

If expectations are unrealistic or contradictory, succession will not fix the problem.

The board should simplify the priorities.

The board should revisit the appointment criteria publicly enough to build confidence

Not confidential interview notes.

But the strategic rationale.

Why this leader.

Why now.

Why these capabilities.

Transition communication should protect external partners

Research partners, regulators and customers need to know decision continuity remains intact.

Major programmes should not appear leaderless during the handoff.

Sources

  1. Reuters, “Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant,” 12 February 2026.
    https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-appoints-beln-garijo-new-ceo-after-deciding-not-renew-current-ceo-hudsons-2026-02-12/

  2. Sanofi corporate leadership announcement and investor communications, 12 February 2026.

  3. Sanofi FY2025 / early 2026 pipeline and strategic communications.

Written by Kevin Abdulrahman
Principal, Executive Authority

Request Counsel → https://executive-authority.com/engage/

Written by

Principal, Executive Authority

Kevin Abdulrahman is the Principal of Executive Authority, a private advisory practice retained by chief executives, board chairs, ministers, and sovereign leaders who require counsel at the level their position demands. His work spans executive communication architecture, board-level positioning, crisis counsel, and the leadership presence that shapes how power is perceived and sustained. Over two decades, he has advised principals in high-stakes negotiations, before boards and cameras, and in the moments that determine institutional legacy.

Published by Executive Authority

Published by
Kevin Abdulrahman — Principal
Request Counsel →
← Back to Insights